 Ceftazidime treatment cystic fibrosis resistant organisms sputum faeces Ceftazidime intravenous agent respiratory tract infections patients cystic fibrosis risks beta lactamases antibiotic resistance high monotherapy emergence resistant bacteria sputum patients mean age patients years equal number male female patients Pseudomonas aeruginosa ceftazidime resistant bacterium respiratory tract colonised patients Ceftazidime resistance aeruginosa isolates colonised patients Ceftazidime resistant organisms faeces patients Eighty cent resistant faecal organisms single isolates resistant organism faeces successive samples patients case ceftazidime resistant enteric isolate sputum Patients aeruginosa ceftazidime resistant enteric organisms non-colonised patients use ceftazidime single intravenous agent exacerbations cystic fibrosis reservoir ceftazidime resistant bacteria